Lansoprazole regimens that sustain intragastric pH >6.0: An evaluation of intermittent oral and continuous intravenous infusion dosages

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 7, 2006, Pages 985-995

  Metz, D C ^a,c   Amer, F ^b   Hunt, B ^b   Vakily, M ^b   Kukulka, M J ^b   Samra, N ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PANTOPRAZOLE; PREVACID SOLUTAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DECOMPOSITION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; FEMALE; HELICOBACTER PYLORI; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DISCOLORATION; INJECTION SITE EXTRAVASATION; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH; TABLET;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; SULFOXIDES; TABLETS;

EID: 33645082691     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02850.x     Document Type: Article

References (20)

1. Longstreth G Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study Am J Gastroenterol 1995 90 206 10
2. Laine L Peterson WL Bleeding peptic ulcer N Engl J Med 1994 331 717 27
3. Lin H-J Lo W-C Lee F-Y et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy Arch Intern Med 1998 158 54 8
4. Lau JYW Sung JJY Lee KK et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers N Engl J Med 2000 343 310 6
5. Leontiadis GI Sharma VK Howden CW Systematic review and meta-analysis: proton pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay - results from the Cochrane Collaboration Aliment Pharmacol Ther 2005 22 169 74
6. Sung JJ Chan FK Lau JY et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison Ann Intern Med 2003 139 237 43
7. Barkun A Racz I van Rensburg CJ et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoprazole vs. ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison Gastroenterology 2004 126 A78 (Abstract)
8. Vorder Bruegge WF Peura DA Stress-related mucosal damage: review of drug therapy J Clin Gastroenterol 1990 12 Suppl. 2 S35 40
9. van Rensburg CJ Hartmann M Thorpe A et al. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer Am J Gastroenterol 2003 98 2635 41
10. Lee KK You JH Wong IC et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer Gastrointest Endosc 2003 57 160 4
11. Barkun AN Herba K Adam V Kennedy W Fallone CA Bardou M High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis Aliment Pharmacol Ther 2004 19 591 600
12. Brunner G Luna P Hartmann M Wurst W Optimizing the intragastric pH as a supportive therapy in upper GI bleeding Yale J Biol Med 1996 69 225 31
13. Metz DC Potential uses of intravenous proton pump inhibitors to control gastric acid secretion Digestion 2000 62 73 81
14. Kovacs TO Lee CQ Chiu YL Pilmer BL Metz DC Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis Aliment Pharmacol Ther 2004 20 883 9
15. Freston JW Pilmer BL Chiu YL et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole Aliment Pharmacol Ther 2004 19 1111 22
16. Freston JW Chiu YL Mulford DJ Ballard ED Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects Aliment Pharmacol Ther 2003 17 361 7
17. Labenz J Tillenburg B Peitz U et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer Gut 1997 41 33 6
18. Kim KA Shon JH Park JY et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 Clin Pharmacol Ther 2002 72 90 9
19. Goldstein JA Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br J Clin Pharmacol 2001 52 349 55
20. Sakai T Aoyama N Kita T et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects Pharm Res 2001 18 721 7